The President & CEO of Regeneron is Exercising Options

By Carrie Williams

Today it was reported that the President & CEO of Regeneron (REGNResearch Report), Leonard Schleifer, exercised options to buy 100 REGN shares at $21.25 a share, for a total transaction value of $2,125.

Following Leonard Schleifer’s last REGN Buy transaction on October 28, 2009, the stock climbed by 386.0%. In addition to Leonard Schleifer, one other REGN executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Regeneron’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $1.93 billion and quarterly net profit of $820 million. In comparison, last year the company earned revenue of $1.58 billion and had a net profit of $174 million. REGN’s market cap is $43.88B and the company has a P/E ratio of 18.90. Currently, Regeneron has an average volume of 544.5K.

Based on 9 analyst ratings, the analyst consensus is Hold with an average price target of $429.38, reflecting a 6.9% upside. Three different firms, including Guggenheim and Oppenheimer, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $54.04M worth of REGN shares and purchased $2,125 worth of REGN shares. The insider sentiment on Regeneron has been negative according to 48 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.